Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a…
In Conversation
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how…
Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was…
It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability…
Promega is a truly global company with a vast international presence. What would you say is the strategic importance that the Benelux affiliate has assumed within…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry,…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from…
Medichem began production at its plant in Malta in 2006. Can you give us a brief overview of the facilities, and of the importance of the…
Actavis’ Maltese operations began as far back as 1976 as a different company ( Pharmamed Ltd.). In 2001, this Malta facility was acquired by Actavis which…
